Financial Archives - Green Market Report

StaffStaffDecember 10, 2020
money-2.jpg

3min2120

 Cannabis wholesale marketplace operator LeafLink has closed on a $40 million Series C investment round, led by Founders Fund. Additional participants include Thrive Capital, Nosara Capital, and Lerer Hippeau. This company said that this latest round of investment brings its venture funding to over $90 million and marks Founders Fund’s largest technology investment in the cannabis space.

The proceeds will be used to expand in current markets by bringing on new brands and retailers, as well as capitalizing on new markets that legalized cannabis following the 2020 election. LeafLink said it will also continue to expand its offerings around payments, delivery, and data & analytics.

“This fundraising round is monumental for a technology company like LeafLink as we continue to define a space that shows no signs of slowing down,” said Ryan G. Smith, Co-founder and CEO of LeafLink. “We’re honored to partner with Founders Fund as we scale our marketplace technology across the growing cannabis industry. Our eyes are set on bringing efficiency and innovation to the supply chain and we’re excited for cannabis to serve as a model for more legacy industries in the future.”  

With the latest round of funding, LeafLink said it will continue to accelerate growth beyond its current $3 Billion of annualized Gross Merchandise Value (GMV).  LeafLink’s marketplace makes up an estimated 32% of U.S. wholesale cannabis commerce. Currently, LeafLink serves 27 markets across the U.S. and Canada with offices in New York City, Los Angeles, and Toronto.

“We invested in LeafLink because the team is merging best practices from e-commerce marketplaces with B2B technology to streamline an entire industry’s supply chain and operations,” said Napoleon Ta, Partner at Founders Fund. “We’re excited to make our largest investment in the cannabis space to date in LeafLink.”

LeafLink’s fundraising is notable since it is a private company. According to Viridian Capital Advisors, most of the cannabis capital that has been raised in 2020 has come from publicly traded companies. Of the 280 deals happening so far in 2020, only 49 have been private company raises, while the other 231 have come from public companies.

 


Kaitlin DomangueKaitlin DomangueNovember 30, 2020
auxly.png

4min2760

Auxly Cannabis Group Inc., (TSX.V – XLY) (OTCQX: CBWTF), leading consumer packaged goods company in the cannabis space, released their financial results for the three and nine months that ended on September 30th. Except for common shares, all figures mentioned will be in Canadian dollars. 

Net Revenue + Gross Profit

The company reported a total net revenue of $13.4 million for the three months that ended on September 30th. Before excise taxes and research contacts, this figure is $15.2 million. Their reported net revenue represents an 85% increase from the previous quarter, and a 732% increase from the same period last year. Last year’s total revenue clocked out at roughly $1.6 million, representing an approximately $11 million dollar difference. 

Auxly categorizes all of their revenue as stemming from the sales of cannabis products, which is their primary responsibility as a business. In addition to producing cannabis CPGs, they have experts in product development and clinical/scientific research to produce these products. The company’s cannabis brands include Dosecann, Kolab Project, Robinsons, and Foray. 

The company reported a gross profit of $3.8 million. 

Net Loss

Auxly experienced a slightly bigger net loss than the same period last year, reporting a net loss of approximately $17.80 million. Last year’s losses capped out at roughly $17.26, so about a 3% change. 

Cash, Assets, and Debt

Auxly reported $13.57 million in cash and cash equivalents for the three month period leading up to September 30th. This is 69% less than what was reported as of December 31st, 2019. Last year’s cash equivalents totaled $44.13 million. Auxly’s currently claims $381,598 in total assets and $112,358 in debt. 

Expenses

Auxly reported a decrease in selling, general, and administrative expenses – dropping down to approximately $11.36 million from roughly $16.59 million during the same time last year. Also, depreciation and amortization totaled $2.3 million. 

Cost of Sales

Auxly sold $9.5 million worth of finished cannabis products during this three month period, with the nine month period totaling $19.66 million. 

Adjusted EBITDA

Auxly reported an adjusted EBITDA of $6.8 million, decreasing 39% from the same period last year. The nine months ending on September 30th, 2020 saw an adjusted EBITDA of roughly $24.2 million, down 10% from the same nine month period in 2019. 

“Our team entered Q3 committed to driving sales growth, reducing costs and improving product availability. Our efforts resulted in a quarter over quarter increase in net revenues of approximately $5 million and a reduction in SG&A of approximately $2 million. Our improved performance was driven primarily by continued improvements in operational and supply chain capabilities, expanding distribution, better alignment of our resources with our commercial objectives and, of course, our continued focus on understanding our consumers and delivering cannabis products that delight them. We believe that our efforts are resonating with consumers and that Auxly has quickly established itself as one of the leading cannabis companies in Canada,” said Hugo Alves, CEO of Auxly. 


Kaitlin DomangueKaitlin DomangueNovember 9, 2020
aurora2.png

5min2450

Canadian-based cannabis company, Aurora Cannabis (NYSE: ACB) reported their Q1 earnings this morning. The results were mixed at best, with shares rising 21% on the potential for cannabis legalization under a Biden administration. Unless otherwise stated, these figures are in Canadian dollars. 

The company’s adjusted gross margin before fair value adjustments on total cannabis net revenue didn’t waver much quarter to quarter, with Aurora Cannabis reporting a 48% adjusted gross margin compared to 50% in Q4 2020. Before fair value adjustments, the company’s adjusted gross margin on cannabis net revenue was 52%. 

Consumer Cannabis 

Aurora reported a slight increase in total and net revenue in Q1, with numbers reaching $67.8 million. Q4’s revenue totaled $67.5 million, so while the increase was small, it was there. 

Consumer cannabis net revenue, however, was down 3% quarter over quarter, reaching a stop at $34.3 million. The adjusted gross margin before fair value adjustments on consumer cannabis net revenue was 38% compared to 35% in the prior quarter. Aurora cites sales mix shifting towards higher margin derivative products as the reason for this increase. 

One area where Aurora really shined in Q1 is in consumer cannabis extracts, with the net revenue increasing by $3.6 million sequentially. Aurora says this was driven by their focus on high-growth extracts such as vapes, edibles, and concentrates, plus a $1.1 million increase in US CBD. 

Medical Cannabis

The company reported a 4% sequential increase in medical cannabis net revenue, ultimately capping out at $33.5 million. Aurora primarily attributes this growth to their strong international medical cannabis presence, which grew a whopping 41% quarter over quarter. 

“Our Q1 2021 results are transitional but do highlight successes across a number of diverse profit pools,” said Miguel Martin, CEO of Aurora. “We remain the leader by revenue in the high-margin Canadian medical market, our international medical business experienced more than 40% net revenue growth this quarter, and our CBD brand Reliva is #1 ranked by Nielsen in the U.S. CBD sector.”

The adjusted gross margin on medical cannabis before fair value adjustments was 59% versus 67% in the prior quarter. This is excluding $2.6 million in ramp up costs at Aurora Nordic 1, which is a large cannabis facility located in Denmark. 

EBITDA

Aurora’s adjusted EBITDA loss was $57.9 million in Q1, with the company including restructuring payments such as contract and employee termination costs of $47.4 million. Excluding these impacts, the adjusted EBITDA loss as defined under the term credit facility is $10.5 million. Aurora says they remain on track to achieve a positive adjusted EBITDA next quarter. 

Cash Use

Aurora Cannabis used $25.2 million cash in Q1 to fund company operations, and used $47.4 million for contract and employee termination costs. This is similar to the prior quarter, however, the use of cash showed significant progress. Cash used to pay for capital expenditures in the first quarter was $15 million compared to $32 million in the prior quarter, as many of their projects are now wrapping up and completing. 

Increased net working capital used $37.0 million in the quarter, driven by a $13.8 million increase in accounts receivable and a $25.1 million increase in inventory.

“While we are not satisfied with our past performance in the growing Canadian consumer business, we have a sense of urgency in the execution of our tactical plan to grow profitable market share. Our efforts are directed at delivering the highest quality products, refocusing on our leading premium and ultra-premium brands, better allocating our sales and marketing spend, and executing key account partnerships at both the province and retail levels.”


Debra BorchardtDebra BorchardtSeptember 17, 2020
MedMen9-1280x720.jpg

4min12920

MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) waiting until the market closed on Wednesday before telling shareholders it picked up another $20 million from lenders and institutional investors. The deal for MedMen includes 10 million in gross proceeds under a new unsecured convertible facility, plus $5.7 million under its senior secured term loan led by Stable Road Capital and $5 million under its senior secured convertible facility led by Gotham Green Partners.

Just what will this cost? It’s not too far from getting an extremely big credit card. The principal amount of the Incremental Notes will carry an interest rate of 18.0% per annum, to be paid as follows: (a) 12.0% shall be paid in cash monthly in arrears; and (b) 6.0% shall accrue monthly to the outstanding principal as payment-in-kind.

“We are pleased with the continued support from our existing capital partners as we continue our recent track record of execution,” said MedMen Executive Chairman, Ben Rose. “The financing package is a significant milestone for the company and is a reflection of the commitment the Company has made to strengthen the balance sheet, accelerate its path to profitability and sustainability, and focus on its core retail business. We look forward to continuing to expand the MedMen brand.”

On September 16, 2020, MedMen closed on an initial $1 million, and has the right to call additional tranches, totaling a million each, no later than 20 trading days from receiving each tranche. Participating lenders will receive a $468,564 fee with a conversion price of $0.20 per share, consistent with the terms of the Facility. MedMen shares were recently selling at $0.17 per share on the OTC marketplace. MedMen has said it will announce its earnings on September 28 after the market closes.

Company Update

While MedMen has struggled over its leadership problems and mountain of debt, it continues to press forward. The company recently noted that it is has 25 retail stores that are in operation across California, Nevada, Illinois, Florida, New York, and Arizona. On August 3, 2020, the City Council of West Hollywood adopted an urgency ordinance to create a new “Legacy Cannabis Business License” which will permanently allow for both medical and adult-use sales of cannabis by MedMen West Hollywood and the three other pre-existing medical operators, bringing the collaborative efforts between the City of West Hollywood and other related parties to a final resolution.

On August 6, 2020, the Massachusetts Cannabis Control Commission voted in favor of granting MedMen Boston, LLC, a subsidiary of the Company, a provisional adult-used license for its proposed flagship retail location near Fenway Park. A final license for this location is subject to meeting various conditions prior to opening, which is expected to occur in 2021.

“The positive licensing developments in West Hollywood and Boston are a result of the Company’s commitment to meaningful engagement with local regulators and the communities we are privileged to serve,” said MedMen Executive Chairman Ben Rose. “We continue forward momentum as we execute on our turnaround plan, strengthen our retail footprint and improve four-wall economics. Through our focus on retail, we have made significant progress in optimizing our business model and improving our presence as partners and neighbors in our locations as we expand the MedMen brand in existing and new markets across the U.S.”


StaffStaffSeptember 10, 2020
shutterstock_1387048082-scaled.png

4min6240

California-based ManifestSeven announced it closed on an aggregate of $10.2 million in gross proceeds raised via three private placements of equity and convertible debt in 2020. In addition to the fundraising, the company said it is close to completing its reverse takeover transaction of P&P Ventures Inc., which is to be renamed ManifestSeven Holdings Corporation. M7 said it expects to begin trading within the coming days on the Canadian Securities Exchange using the ticker symbol “MSVN”.

ManifestSeven is an omnichannel platform for legal cannabis, merging compliant distribution with a retail superhighway. M7, with offices in Commerce and Irvine, California. The company said it has a growing portfolio of owned and operated retail operations located in major metro markets, including brick-and-mortar dispensaries, local on-demand delivery services, e-commerce, and subscription offerings.

“Today’s announcement is a resounding affirmation of M7’s business model and corporate resilience in the face of economic headwinds, making us one of the few cannabis companies to raise capital in this environment successfully,” said Sturges Karban, Chief Executive Officer of ManifestSeven. “We are truly encouraged by this level of financial backing from the investment community, which solidifies M7’s position as one of the leading operators in the legal cannabis market. This injection of capital allows M7 to continue expanding our seamless, compliant omnichannel across California, and eventually evaluate other markets in North America as opportunities arise.”

Capital Raising

Earlier this year, the M7 completed a unitized private placement offering at a purchase price of $4.50 per unit, with each unit consisting of one M7 share and one half warrant exercisable to acquire M7 shares at an exercise price of $6.75 per Share. Pursuant to the 2020 Private Placement, M7 has issued units for aggregate gross proceeds of approximately $2.3 million.

M7 completed a private placement offering in August of an aggregate principal amount of approximately $2.5 million in subordinated secured convertible promissory notes, which carry non-compounding interest at a rate of 15% per annum over an 18-month term, with the outstanding balance of principal and accrued interest convertible into Shares. The holders of the 15% Convertible Notes were also issued non-transferable warrants exercisable to acquire the number of Shares that such holder is entitled to upon the conversion of the 15% Convertible Notes at an exercise price equal to the conversion price until the date that is three years from the date of the CSE listing. As a result of the completion of the RTO, the 15% Convertible Notes constitute an obligation of the Resulting Issuer.

M7 completed a private placement offering in September of an aggregate principal amount of approximately $5.4 million in subordinated secured convertible promissory notes, which carry non-compounding interest at a rate of 17.5% per annum over an 18-month term, with the outstanding balance of principal and accrued interest convertible at a conversion price (the “17.5% Note Conversion Price”) of $1.17 per share (subject to certain adjustments). The holders of the 17.5% Convertible Notes were also issued warrants exercisable to acquire the number of Shares that such holder is entitled to upon the conversion of the 17.5% Convertible Notes at an exercise price equal to the 17.5% Note Conversion Price until the date that is three years from the date of the CSE listing. As a result of the completion of the RTO, the 17.5% Convertible Notes constitute an obligation of the Resulting Issuer.

 


Debra BorchardtDebra BorchardtJuly 20, 2020
hemp_0.jpg

5min15850

GenCanna, one of Kentucky’s largest hemp companies, filed for voluntary Chapter 11 reorganization with the U.S. Bankruptcy Court in the Eastern District of Kentucky earlier this year in February. One problem with GenCanna’s bankruptcy filing though was that MariMed (OTC:MRMD) was one of the largest shareholders in the company. It had a $34 million claim against the company sparking a battle over control of the company.

Last week, Law360 reported that MariMed lost a round over the efforts to gain control over the company. The website said that U.S. Bankruptcy Judge Gregory Schaaf of Kentucky found MariMed had acted improperly when it attempted to replace members of GenCanna’s board of directors and force out GenCanna’s president and chief executive officer.

The Fight Begins

In any bankruptcy cases, debtors are first in line over equity holders. In the process of working through its bankruptcy, GenCanna made a deal to sell the bulk of its assets for $75 million. MariMed was against the deal and had its own plan to reorganize the company, but apparently couldn’t come up with the money needed for the plan. According to the Law360 reporting, the court records demonstrated that GenCanna went with the offer it had.

The court records said that MariMed’s president and chief executive officer Robert Fireman, who also sits on GenCanna’s board of directors, teamed up with another board member, Michael Falcone, to form a voting bloc controlling 52% of GenCanna’s parent company’s shares. The two apparently pulled GenCanna Chief Executive Officer Matty Mangone-Miranda, GenCanna President Steve Bevan, and one other member of the board of the parent company, and installed Fireman as chairman, according to court records.

The court filings stated that Fireman and Falcone appointed a new CEO of the parent company, and directed him to get the bankruptcy case dismissed. The new director of GenCanna USA’s board was told to develop a plan to liquidate the company within 30 days.

The ousted executives, Mangone-Miranda and Bevan asked Judge Schaaf to step in claiming MariMed’s actions violated board rules. The Judge agreed saying, “Using an equity position that has no chance of recovery to object to a settlement that is not even filed is an obvious attempt to exercise control over the case and enhance the creditor interests,” Judge Schaaf wrote. “Further, this also suggests clear abuse of the governance process that would warrant action in this court if an injunction was requested. For now, that analysis is not required.”

Basically, since the assets were sold, there is nothing left for the equity owners like MariMed. Since there’s nothing left for MariMed, they have no power to make these types of decisions at the company. GenCanna said it is in settlement negotiations with its senior secured lender and buyer to resolve claims from the committee of unsecured creditors. The settlement is expected to generate roughly $1 million, but the claims are much higher than that.

The assets were sold to New York-based MGG Investment Group, a private lender, and one of the company’s creditors.

GenCanna’s Pain Inflicted On MariMed

GenCanna’s bankruptcy filing also weighed on the shares of MariMed. In April, MariMed’s fourth-quarter 2019 financial results included a one-time charge of $30.2 million as a result of a write-off of its investment in GenCanna. CEO Jon Levine said, “Despite GenCanna’s Chapter 11 filing, we believe that it will emerge with a restructured capital and operational structure that will allow GenCanna to restore its position as a leader in the hemp industry. If this occurs, we believe there will be an opportunity for the value of the assets to be recaptured at a later date.  We expect to continue our strong relationship with GenCanna and jointly pursue opportunities in the evolving hemp industry.”

MariMed’s shares have dropped from 40 cents in February before the GenCanna bankruptcy and were lately selling at 13 cents.


Debra BorchardtDebra BorchardtJuly 17, 2020
1933.jpg

5min7702

1933 Industries Inc.  (CSE: TGIF) (OTCQX: TGIFF) reported that it has agreed upon a non-brokered financing of up to C$5,000,000. 1933 said that the offering will consist of the sale of up to 66,666,666 units at a price of C$0.075 per Unit. The offering is expected to close on or about August 14. The stock was lately selling at C$0.07. The proceeds will be used for ongoing business development and general working purposes.

1933’s CEO Paul Rosen said, “1933 Industries has the assets in place to build a self-sustaining and profitable business. Our new cultivation facility in Las Vegas is now running at full capacity and we have launched new hemp and CBD wellness products and opened up new sales channels, including through Amazon and Walmart. We have cut our public entity expenses by 68% and our non-operating expenses by 46% since November 2019, and we continue to move aggressively to control costs. This financing will strengthen our balance sheet and provide additional cash reserves to manage COVID-19 related uncertainty while we execute on our strategy.”

The company has two subsidiaries and controls all aspects of the value chain with cultivation, extraction, processing, and manufacturing assets supporting its diversified portfolio of cannabis brands and licensing partners. 1933 owns 91% of Alternative Medicine Association, LC (AMA), and 100% of Infused MFG LLC.

Brands include: AMA flower and AMA concentrates, as well as CBD-infused Canna Hemp™, Canna Hemp X™, and Canna Fused™ products. Partners under licensing agreements include: Birdhouse Skateboards™, Blonde™ Cannabis, Bloom™, Denver Dab Co., Grizzly Griptape, OG DNA Genetics, The Pantry Company, PLUGplay, and The Original Jack Herer®.

Wal-Mart

1933’s Canna Hemp announced earlier this week that it has made its products available for sale through the retail giant, Walmart.com. Walmart currently occupies one of the top spots in the hierarchy of online retail, as one of the largest online retailers for supplements and natural health products. Health products have been a major seller within Walmart.com’s online marketplace, and Walmart expects online sales to grow by more than thirty percent by the end of 2020.

“Walmart has been the next natural move for Canna Hemp, as the brand continues its expansion throughout 2020. Understanding the online marketplace and maintaining a stable e-commerce presence is vital for success in today’s web-based economy. Currently, Canna Hemp’s products are available through its website, cannahemp.com, as well as a host of other e-commerce sites, with more to come as the brand continues to grow.”

Deal Terms

Each Unit will consist of one common share of the Company and one half of one transferable share purchase warrant. Each whole share purchase Warrant will entitle the holder to acquire one Common Share at an exercise price of C$0.125 per share for a period of 24 months following the closing date of the Offering. The net proceeds of the Offering will be used to fund the Company’s ongoing business development and general working capital.

Each Warrant is subject to an accelerated expiry. If the closing price of the company’s common shares exceeds C$0.25 per share for a period of 10 consecutive trading days, the company may provide notice of acceleration, after which holders of the Warrants will be entitled to exercise their Warrants for a period of 30 days. All securities in respect of the Offering will be subject to a four month and one day hold period commencing on the Closing Date.

The company recently announced amendments to its convertible debentures, including the deferral of interest payments to the maturity date in September 2021 (refer to news release dated June 29, 2020).


Debra BorchardtDebra BorchardtJuly 16, 2020
creditcard.jpg

10min15721

The dispensary credit card fraud scheme that has ensnared the delivery company Eaze is set to move forward.

In March, Ruben Weigand and Hamid “Ray” Akhavan were charged with conspiracy to commit bank fraud over charges that occurred between 2016 and 2019. They are alleged to have created a bunch of fake companies to trick banks into processing credit and debit payments for marijuana products from legal sellers. The two asked the court to dismiss the indictment saying that no one was harmed in the scheme.

[The major credit card companies have refused to work with the cannabis industry as it is still federally illegal. This has caused major difficulties for retailers whose customers are accustomed to using debit and credit cards for most transactions. Numerous workarounds have been devised like installing ATM machines in dispensaries or creating a transaction where the buyer is making a debit transaction versus a credit card transaction.]

The two also argued that in addition to no one being harmed, “the Rohrabacher-Farr Amendment, a rider on a congressional appropriations bill that bans the U.S. Department of Justice from using its funding to prosecute businesses engaged in a state’s legal medical marijuana industry.”  Law360 has reported that “on Wednesday, the government said the amendment has nothing to do with charges of conspiracy to commit bank fraud. The allegations center on the pair’s efforts to mislead the banks, which is a crime no matter what industry is involved.”

“The indictment clearly alleges facts showing that the issuing banks maintained a property interest in the funds they used to settle credit and debit card transactions for their cardholders, and that the banks issued such payments as a direct result of the deceptive scheme outlined in the indictment,” the prosecutors wrote.

Eaze Not Named

Prosecutors said Weigand and Akhavan worked with executives at an online marijuana marketplace company to facilitate the sales, although they haven’t named the business. Eaze, an online company offering delivery from dispensaries, was the subject of a lawsuit last year that alleged it worked with Akhavan to utilize shell companies to process credit card payments.

While Eaze was not specifically named in the case by the prosecutors, only an unnamed online marijuana marketplace was mentioned, a connection has been made. Eaze was not charged in this case against the two.

The Eaze Connection

In a lawsuit filed in 2019, Herban accused Eaze of ongoing, pervasive criminal activity. It should be noted that this case was dismissed by parties in January 2020 according to Law 360. Eaze was not charged.

 To gain an unfair competitive advantage in the California cannabis delivery market, Eaze is directing,
coordinating, and participating in a scheme to defraud credit and debit card companies and financial
institutions into processing cannabis transactions in violation of a host of criminal laws, including
prohibitions against: (1) wire fraud (18 U.S.C. § 1343); (2) bank fraud (18 U.S.C. § 1344); and (3)
criminal fraud (Cal. Pen. Code § 532). By running a business that avoids the constraint of California
and federal laws, Eaze has obtained an unfair advantage over its competitors, including Herban,
who have been harmed and continue to be harmed by Eaze’s ongoing criminal acts.
To perpetrate these frauds, Eaze created or partnered with Cyprus- and U.K.-
based shell corporations that purport to sell these seemingly innocuous products but in fact exist
solely or primarily for the purpose of misrepresenting the nature of the underlying transactions (the
“Eaze Shell Companies”).
Herban owned Chill, a group of former Eaze employees that split off to create a competing platform. Back in April 2019, the company DionyMed terminated its contract with Eaze and claimed that “Based on review by outside counsel, DYME could not confirm that the processing procedure meets California regulatory requirements.” The company said it was going to invest in its own delivery service called “Chill.” DionyMed through its dispensary store Hometown Hearts claimed that Eaze was using shell accounts to create fraudulent charges and payment processing, which was the excuse it needed to terminate a three-year contract.
Eaze countersued and claimed in its countersuit that Hometown Heart knew that the payment processors it accused of fraud, were its own processors, not Eaze’s. Eaze has said repeatedly, “It doesn’t process claims.”
In its customer delivery receipts, Eaze tells its customers that they will see the charge for their purchase through Eaze on their card statement, and that the charge will be associated with some entity other than the actual merchant from whom they purchased the product. The customer delivery receipts reflect an express promise by Eaze to submit false information into the credit and debit card payment system, which Eaze does, on information and belief, to ensure that the transactions are not flagged or caught by the Payment Card Companies as Precluded Activities.
The complaint went on to say:

Eaze worked with an individual named Hamid “Ray” Akhavan (“Akhavan”) in an effort to restart credit and debit card processing on the Eaze Platform. Eaze directed several cannabis dispensaries, including some of its largest partners, to

meet with Akhavan in Calabasas, California regarding a new credit and debit card solution. In or around March or April 2018, at Eaze’s direction, representatives from various dispensaries attended the meeting with Akhavan in Calabasas (hereinafter the “Akhavan Meeting”). On information and belief, when the representatives for the dispensaries arrived at the meeting
location, Akhavan’s ostentatious purple Lamborghini was parked outside.

Are The Dispensaries Guilty?

Eaze quit accepting payments of this nature in mid-2019. However, the allegations don’t end because the transactions ended. The dispensary owners are no doubt nervously watching the outcome of this case. They could also be dragged into this for committing bank fraud. The case uses the term “conspiracy,” indicating that it isn’t just these two and that others could be involved. If the dispensary owners knew that Vias and Mastercard would not accept payments for cannabis transactions and they still pursued a scheme that managed to make that happen, are they guilty?
At least while cannabis foe Attorney General Bill Barr is at the top of the Department of Justice, the dispensaries are probably right to be worried. Some dispensaries tried to back out of the Eaze deal and were refused by Eaze who told them they had to meet certain volume goals.

In a statement, Eaze said the company is aware of the case and is “fully cooperating with the relevant authorities. Eaze transitioned to supporting new payment systems over a year ago, and this matter does not impact the current customer experience.”

 

 


StaffStaffJuly 15, 2020
shutterstock_557364895.jpg

3min4940

Cannabis technology company POSaBIT Systems Corporation (CSE: PBIT) reported rising revenue for the first quarter of 2020 and said it expects to meet its prior forecast for revenue of $8 million for the year of 2020. Total revenue for the quarter ending March was $972,000, up 5% compared with $897,000 in the first quarter of 2019.

The net loss for POSaBIT was $792,743, which was slightly higher than last year’s net loss of approximately $774,000 for the same time period. The gross profit was $70,833 an increase of 192% compared with a gross profit of $36,797 in the first quarter of 2019. The company engages in blockchain-enabled payment processing and point-of-sale systems for cash-only businesses.

“We are pleased to witness continued strong demand for our retail payment and POS solutions even amid the ongoing pandemic,” said Ryan Hamlin, co-founder, and CEO of POSaBIT. “POSaBIT is also excited to provide updated guidance that we will be cash-flow positive in Q3 2020, a change from our prior guidance of Q4 2020. Customer desire to avoid cash payments is leading to an increased usage of our solutions in our current stores. At the same time, we are witnessing a significant uptick in interest from stores that have previously been cash-only operations. Sales have increased at a rapid pace and we expect to meet our prior 2020 forecast guidance of over $8M in revenue and over $135M in transactional sales.”

Looking Ahead

POSaBIT updated its full-year 2020 outlook with a forecast that revenue would grow in the range of approximately 75% to 95% year over year. The company gave new guidance that it would reach profitability in the third quarter of 2020. Transactional sales are projected to grow over 200% to approximately USD $135 million, assuming the average store processes between USD $350,000 and USD $600,000 per year through the POSaBIT service. Cost of sales in the range of $3.5 million to $4.0 million and the company said it plans to expand POSaBIT’s footprint to end 2020 in 15 to 20 recreational and medical states.



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE


Back to Top

You have Successfully Subscribed!